Quick Overview: Elizabeth Plimack, MD, MS, of the Fox Chase Cancer Center, Philadelphia, PA talks about The Ahmad Tarhini, MD, PhD, H. Lee Moffitt Cancer Center, Tampa, FL, discusses the Phase II Ticiana A. Leal, MD, medical oncologist, ​team leader, University of Wisconsin Carbone Cancer Center Thoracic Malignancies ...

About Ecog Acrin - Detailed Overview & Context

Elizabeth Plimack, MD, MS, of the Fox Chase Cancer Center, Philadelphia, PA talks about The Ahmad Tarhini, MD, PhD, H. Lee Moffitt Cancer Center, Tampa, FL, discusses the Phase II Ticiana A. Leal, MD, medical oncologist, ​team leader, University of Wisconsin Carbone Cancer Center Thoracic Malignancies ... In this segment, Dr. Mark R. Litzow provides an in-depth look at the ... legacy groups of uh of energy and with Richard C. Zellars, MD, talks with Jean Wright, MD, about the NRG Oncology/RTOG 9804 and

Sunil Badve, MD, FRCPath, Emory School of Medicine, Atlanta, GA, comments on the secondary analysis of the Naomi Allen, BSc, MSc, DPhil is Co-Chief Scientist for UK Biobank and Professor of Epidemiology at the Nuffield Department of ... Presented at SAYAO 2014 - Breaking Barriers in Acute Lymphoblastic Leukemia. Pamela L. Kunz, MD, Yale University School of Medicine, New Haven, CT, reports on the final analysis of efficacy and evaluation ... Rick Baehner, MD, from Exact Sciences, discusses the significance of DCIS biosignature reclassified patients who met RTOG 9804 or

Brief orientation to the NCI CIRB and the most common functions and interactions that a site will have with the NCI CIRB in the ... Jennifer R. Eads, MD, physician lead, GI Cancer Research, director, National Clinical Trials Network, Abramson Cancer Center, ...

Photo Gallery

About ECOG-ACRIN
The ECOG-ACRIN E2810 study: pazopanib for patients with mRCC
KEYNOTE-604 and ECOG-ACRIN 5161 Trials for ES-SCLC
ECOG-ACRIN EA6194: neoadjuvant pembrolizumab & vidutolimod in melanoma
Dr. Leal on the Rationale for the ECOG-ACRIN EA5161 Trial in ES-SCLC
ECOG-ACRIN E1910 Study On Blinatumomab In ALL Treatment – Dr. Mark R. Litzow
Resources & Support for Integrating PROs in ECOG-ACRIN Trials Webinar
SABCS Snippets: Results from the NRG Oncology/RTOG 9804 and ECOG-ACRIN E5194 Trial
ECOG-ACRIN EA1131: post-NACT TILs and intrinsic subtype in residual TNBC
Randomized Phase II US Intergroup Study ECOG-ACRIN E1412
Overview of the NCI Cooperative Groups
ASCO 2024 - LBA503: ECOG-ACRIN EAZ171
Sponsored
Sponsored
View Main Result
Sponsored
Sponsored